Jiangxi TCM maker best known for Jianwei Xiaoshi Pian, a widely sold digestive-aid tablet, under the China Resources group.
Jiangxi TCM maker best known for Jianwei Xiaoshi Pian, a widely sold digestive-aid tablet, under the China Resources group.
Relies on one over-the-counter tablet for much of its revenue and spends heavily on advertising and pharmacy-chain promotion to keep it in front of shoppers, so marketing outlay and a single brand's fortunes shape results. Sold mainly through pharmacy chains and distributors.
In one line: A Chinese TCM digestive-remedy maker (like a herbal Tums).
Moat: narrow (brand, distribution). Long-established OTC digestive brand with China Resources group distribution support.
Headquarters: Nanchang, Jiangxi, China · Employees: 4,352
Size China Resources Jiangzhong Pharmaceutical (600750.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.27B, the 1061st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.88 on 18 Nov 2026.
Performance Over six months the shares gained 3.8%, against -3.5% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 10.2% over the last twelve months (peer median +10.2%); the operating margin is 23.6% (peer median 15.0%).
Valuation It trades at 16.5× forward earnings against a peer median of 16.9× (9th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.95B | CN¥4.18B | CN¥4.40B | CN¥4.52B | CN¥3.85B |
| Revenue growth | — | -5% | -3% | +17% | — |
| Gross profit | CN¥2.65B | CN¥2.67B | CN¥2.73B | CN¥2.82B | CN¥2.42B |
| EBITDA | n/a | CN¥1.17B | CN¥1.03B | CN¥966M | CN¥744M |
| Net income | CN¥841M | CN¥907M | CN¥788M | CN¥719M | CN¥598M |
| Free cash flow | CN¥891M | CN¥738M | CN¥569M | CN¥870M | CN¥730M |
| Capital expenditure | CN¥229M | CN¥281M | CN¥291M | CN¥211M | CN¥346M |
| Total debt | CN¥637M | CN¥355M | CN¥6.29M | CN¥56.6M | CN¥89.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% |
| Chongqing Taiji Industry (Group) 600129.SS | $982M | -20% | -4% | 2% | 69.8× | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600750.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -1.3% | 7th highest of 21 |
| 6-month return | +3.8% | -3.5% | 9th highest of 21 |
| Distance from 52-week high | -14.2% | -26.3% | 7th highest of 21 |
| Revenue growth (TTM) | -10.2% | +10.2% | 2nd lowest of 21 |
| Operating margin | 23.6% | 15.0% | 7th highest of 21 |
| Forward P/E | 16.5× | 16.9× | 9th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -1.9% | 2.1% | 6th least demanding of 20 |
| Growth delivered (Del g) | +11.6% | +5.9% | 6th highest of 20 |
| Hurdle (Req g minus delivered) | -13.5 pp | -8.0 pp | 7th least demanding of 20 |
| ROIC minus cost of capital | +10.3 pp | +2.7 pp | 6th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% | +0.6% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $2.97B | -7% | -4% | -13% | n/a | 5.0% | +1.0% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.00B | +11% | -14% | 9% | 91.7× | 33.8% | +5.9% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Bausch Health Companies BHC.TO | Canada | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% | +5.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% | -2.2% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |